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ABSTRACT

An auxiliary substance such as a label, support, or bi
oactive agent is attached to a protein at a site that is
remote from the active site of the protein by the use of
exopeptidase and a nucleophile which is an amino acid,
amino acid derivative, amine or alcohol. In one embodi
ment, the nucleophile is attached to the carboxy termi

nus of a protein by catalysis with exopeptidase to form

an adduct and then the adduct or its combination with

a linker arm is bound to the auxiliary substance. In
another embodiment, the auxiliary substance or its com

bination with a linker arm is bound to the nucleophile to
form an intermediate substance which is then coupled
by catalysis with exopeptidase to the carboxy terminus
of a protein.

Field of Search ................. 435/41, 174, 177, 181,

7 Claims, 2 Drawing Sheets
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EXOPEPTDASE CATALYZED STE SPECIFIC

BONDING OF SUPPORTS, LABELS AND
BOACTIVE AGENTS TO PROTENS

CROSS-REFERENCE TO RELATED
APPLICATION

This application is a continuation-in-part of U.S. pa
tent application Ser. No. 07/375,138, filed Jun. 30, 1989.
TECHNICAL FIELD
This invention relates to immobilized and labeled

proteins and to the attachment of proteins to bioactive
agents. Specifically, it relates to methods for attaching
labels, immobilization supports and bioactive agents to
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cially applicable to immobilization, is the capability for
repeated use and for a high packing density. The fourth
is the avoidance of attachment of the support, label or
agent within or in the vicinity of the active site of the
protein. Otherwise, the resulting loss of functional ca
pacity often causes inadequate reactivity and the need
to use more protein.
One of the most important protein embodiments
being investigated today is the antibody. The need to
minimize the attachment of immobilizing supports, la
beling groups or bioactive agents within or near the
antigen-binding site of an antibody is widely recog
nized.

One method for such minimization involves binding
antigen
to the antibody prior to reaction with the label
specific sites of proteins.
ing group, bioactive agent, or immobilizing support. In
this manner, the antigen shields the antibody binding
BACKGROUND OF THE INVENTION
site from reaction. The success of this shielding method,
It is well-known that the function of bioactive prote however,
is limited. Although a high affinity of the
ins can often be enhanced by their combination with antibody for the antigen exists, the equilibrium between
other substances. When used to catalyze a reaction or to
antibody/antigen complex and the free an
obtain separation, proteins can be immobilized to in the
tibody/antigen
enables free antibody to react. This has
crease reaction efficiency and simplify the processing. foreseeable negative
In addition, expo
When used as detecting agents, proteins can be labeled sure of the antigen to consequences.
a
labeling
group,
bioactive agent,
25
to facilitate measurement. When used to complex with
immobilizing support often results in attachment of
or treat biological organisms, proteins can be combined or
to the antigen.
with bioactive agents (hereinafter called "augmenta thatThematerial
known
methods for immobilizing, labeling or
tion') to help achieve treatment efficacy.
any kind of protein fall far short of main
Methods for immobilizing proteins are desirable be augmenting
the functional capacity of the protein. Protein
cause they localize reaction sites and improve economic taining
recovery. Moreover, immobilized proteins are gener reactivity is generally lessened. Proper spatial orienta
ally less susceptible to the loss of activity due to chemi tion and packing density are often lacking. And, as a
cal attack and changes in temperature and pH than are result, many attendant economic, toxic, reactive and
non-specificity problems occur. Consequently, better
free proteins.
Methods for labeling or augmenting proteins are 35 and more specific methods for binding labels, supports
desirable because they facilitate quantification, localiza or bioactive agents to proteins are needed.
It is an object of the invention, therefore, to develop
tion, specificity and reactivity of the protein. The result
ing combinations, moreover, are the resulting combina methods for labeling, immobilizing or bioactively aug
tions and/or powerful tools for clinical analysis and menting proteins at sites remote from the functionally
treatment.
active site or sites of the protein. It is also an object of
Numerous techniques exist for protein immobiliza the invention to immobilize proteins by covalently bind
tion on solid supports. Proteins can be physically ad ing them to an inert immobilization support. Another
sorbed onto inert supports or can be covalently bound object of the invention is to covalently bind a label to a
to the support through reaction with bifunctional linker specific site of a protein. Another object is to covalently
arms. Microencapsulation, gel entrapment and com 45 bind bioactive agents to a specific location on a protein.
plexation (with ion exchange resins) also can bind and A further object of the invention is to immobilize prote
immobilize.
ins so that they have the correct spatial orientation and
Numerous techniques also exist for binding labels and packing density which will allow unhindered access to
bioactive agents to proteins. Most of these techniques the functionally active site.
call for reaction of the label or agent and a functional
SUMMARY OF THE INVENTION
group of the protein, such as an amino group, which
occurs repeatedly throughout the protein. Although
These and other objects are achieved by the present
some repetitions of such a group are shielded from invention which is directed to methods for immobiliz
binding by the conformation of the protein, many others ing, labeling and augmenting proteins. Generally, the
are exposed and available for binding with the labeling 55 method involves binding the immobilization support,
group or bioactive agent. The result is a mixture of label or bioactive agent (hereinafter called "auxiliary
proteins having labels or bioactive agents attached at substance') to a protein at a specific site so that interfer
various nonspecific sites.
ence with the function and performance of the protein is
With any of these techniques for immobilizing, label minimized or eliminated. Preferably, this specific site is
ing or augmenting, several criteria should be met. The highly remote from the active sites of the protein.
first is a correct spatial orientation for optimum reactiv
In particular, the method of the invention involves
ity of the proteins. A protein functions best when it is two primary reactions. The first (hereinafter called the
bound in a fashion that orients its active sites away from "primary coupling reaction"), catalytically couples an
the support, label or bioactive agent and renders the amino acid, an amino acid derivative, an amine or an
sites available for functional operation. The second is 65 alcohol (hereinafter called "nucleophile"), to the car
the exhibition of protein activities and specificities that boxy terminus of the protein through the use of an
are at least comparable to those exhibited by the un exopeptidase enzyme. The second (hereinafter called
bound form of the protein. The third, which is espe the "primary binding reaction'), binds the side chain of
15
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the nucleophile to a specifically reactive group attached
to the auxiliary substance.
The method of the invention can be practiced by
alternative synthetic routes depending on whether the
primary coupling reaction or primary binding reaction
is conducted first. These two routes are depicted in the
scheme presented in the following section entitled De

4.

the side chain is chosen so that the amino acid nucleo

phile has a distinctive character relative to the amino
acids of the protein. With this design, the amino acid
nucleophile rather than the amino acids of the protein is
selectively and preferentially reacted with a specifically
reactive group of the linker arm or auxiliary substance.
When the second synthetic route is employed, such a
distinctive character can be used but is not necessary
because the primary coupling reaction provides the
selectivity desired.
The amine nucleophile used in the method of the
invention mimics the amino acid nucleophile. It is a C2
to C20 aliphatic, aromatic or arylaliphatic primary
amine having a reactive substituent along its backbone
or at its other terminus. The foregoing conditions re
garding the character of the amino acid side chain also
apply when an amine is employed in the first and second
synthetic routes.
The alcohol nucleophile used in the method of the
invention is an aliphatic, aromatic or arylaliphatic C1 to
C20 primary alcohol having a reactive substituent along

tailed Description of the Invention.
The first synthetic route can be employed with all
sizes and solubilities of reactants. A nucleophile having 10
a distinctive side chain is first coupled to the carboxy or
carboxy ester terminus of the protein by the primary
coupling reaction. This coupling either adds the nucleo
phile to the carboxy terminus of the protein (condensa
tion) or substitutes the nucleophile for the amino acid 15
residue forming that carboxy terminus (transpeptidation
with amino acid or amine or transesterification with
alcohol) or substitutes the nucleophile for the alcohol
group of a terminal amino acid ester residue. The result
ing protein-nucleophile adduct is then bound to an aux 20
iliary substance by the primary binding reaction which
takes advantage of the distinctive character of the side its backbone or at its other terminus.
chain. The adduct either is directly bound to the auxil
The linker arm used in the method of the invention is
iary substance or is indirectly bound through a bifunc a flexible or semi-flexible chain which has as its termini
tional linker arm. In either case, the binding reaction 25 (1) a specifically reactive group that is reactive with the
occurs between the side chain of the nucleophile and a side chain of the nucleophile and (2) an other functional
specifically reactive group on the auxiliary substance or group that reacts with a combining group of the auxil
linker arm.
iary substance.
The second synthetic route can be employed when
Immobilizing supports useful in the present invention
the molarities of the reactants in the reaction medium 30 are inorganic or organic materials which may be func
are sufficient to permit relatively rapid enzymatic cou tionalized with a specifically reactive group for selec
pling. A nucleophile is first bound to the auxiliary sub tive reaction with the side chain of the nucleophile, or
stance by the primary binding reaction to form an inter with a combining group that reacts with the other func
mediate of the auxiliary substance and nucleophile. The tional group of the linker arm. The support is a porous
binding can be accomplished by direct reaction of the 35 or semiporous material that is biologically inert and
side chain of the nucleophile and the auxiliary substance insoluble in the medium used.
or indirectly through a linker arm that has been pre
Bioactive agents include those that act to provide a
bound to the auxiliary substance. The intermediate is desirable biochemical or therapeutic result. They may
then coupled to the carboxy terminus of the protein by be functionalized with a specifically reactive group for
the primary coupling reaction. Transpeptidation, con reaction with the side chain of the nucleophile, or with
densation and transesterification with amino acid, a combining group that reacts with the other functional
amino acid derivatives, amine or alcohol nucleophiles group of the linker arm. Included are chemotherapeutic
can all be employed in this primary coupling reaction. agents, oxidizing or reducing agents, cytotoxic agents,
The proteins used in the method of the invention are anticancer agents, radioactive agents, antibiotics, an
biologically-active polypeptides. Included without limi 45 timicotics, anti-infectives, heavy metal agents, antiviral
tation are enzymes, enzyme inhibitors, peptide hor agents, lysing agents, chelating groups and the like.
mones, DNA binding proteins, reading frame proteins,
Labels useful in the present invention include fluores
transcriptases, antibodies, Fabtruncated antibodies, anti cent groups, phosphorescent groups, colorimetric
body fragments, regulating proteins, peptides as small as groups, radioactive groups, luminescent groups, spec
two residues and various other functional proteins.
trometric groups nuclear magnetic resonance groups,
The preferred proteins for use in the inventive electron spin resonance groups and other groups with
method are monoclonal or polyclonal antibodies. Pre physiochemical properties that may be detected by
ferred classes of antibodies include those that function
measuring means. These labels may be functionalized
to detect antigens in biological systems or contaminants with a specifically reactive group for reaction with the
in biological or inanimate systems, to carry bioactive 55 side chain of the nucleophile, or with a combining
agents to specific sites, to diagnose disease and organic group that is reactive toward the other functional group
disfunction, to separate antigens from other materials in of the linker arm. The nucleophile may also function as
biological or inanimate systems, and to remove antigens a label when it carries radioactive atoms.
from biological or inanimate systems. Especially pre
The enzymes that carry out the primary coupling
ferred embodiments are mammalian immunoglobulin 60 reactions are exopeptidases. They act specifically at the
proteins from the IgA, Igld, IgE, IgM, or IgG class of C-terminal end of peptide chains to form or transform
immunoproteins.
peptide bonds under basic conditions (condensation and
The amino acid nucleophile used in the method of the transpeptidation) or acidic conditions (transesterifica
invention is an alpha amino acid or amino acid deriva tion) and are relatively stable under the reaction condi
tive having a side chain with a reactive substituent. 65 tions used.
Alternatively, it may have a simple, nonfunctional side
Preferred groups of exopeptidases for the method of
chain in circumstances where it is also the auxiliary the invention are serine carboxypeptidases. Certain of
substance. When the first synthetic route is employed, these enzymes, known as carboxypeptidase Y, are spe

5,234,820

5
cific for amino acids, or amines with neutral or basic

6

reactive substituent and the auxiliary substance or com
side chains. Certain other classes of carboxypeptidase bination has a reactive group that is reactive toward the
enzymes are specific for amino acids with acidic side reactive substituent of the nucleophile, and (b) coupling
chains. Correlation of the exopeptidase enzyme speci the intermediate to the protein by non-neutral catalysis
ficity and the neutral, acidic or basic character of the with an exopeptidase enzyme to form the bound pro
nucleophile to be coupled to the protein is appropriate tein.
according to the method of the invention.
According to either of these two methods, the auxil
The conditions for the enzymatically catalyzed reac iary substance may be an immobilization support, a label
tion between the protein and the nucleophile include or a bioactive agent. It is preferred that the methods
control of pH, temperature, concentration and incuba 10 employ the combination of the auxiliary substance co
tion time.
valently bound to the linker arm having the specifically
The present invention is also directed to methods reactive functional group terminating the free end of
which employ the labeled, immobilized or augmented the linker arm. Under basic catalysis conditions, it is
protein.
preferred that the nucleophile is an amino acid, amino
The method for use of the labeled protein involves 15 acid derivative or amine. Under acidic catalysis condi
combining of the labeled protein and the material upon tions, it is preferred that the nucleophile is an alcohol. It
which it is to act, removing any excess labeled protein is further preferred that catalysis conditions include a
and measuring the amount of labeled protein that has rapid incubation time. Amino acid nucleophiles may
interacted with the material. In particular, this method include aliphatic amino acids, hydroxy amino acids,
is useful for detection of antigens or enzymatic sub sulfur-containing amino acids, diamino monocarboxylic
strates/inhibitors by antibodies or enzymes, respec acids, aromatic amino acids, heterocyclic amino acids,
tively.
and activated derivatives thereof. It is preferred that the
The method for use of immobilized protein proceeds amino acid nucleophile is serine, taurine, or alanine.
in a known manner as indicated by the character of the
The protein in either method may be an antibody, an
protein. The protein preferably is an enzyme, antibody, 25 enzyme, an enzyme inhibitor, a protein hormone, a
DNA binding protein or regulatory protein. The pre DNA binding protein, a regulatory protein or a DNA
ferred uses will include enzymatically catalyzed reac reading frame protein. It is preferred that the protein is
tions, antibody-antigen complexations, regulation of a monoclonal or polyclonal antibody, and that the nu
reactions and DNA or enzyme separations and/or puri cleophile is substantially completely bonded to the car
fications. One advantage of this method is the increased 30 boxyl terminus of the heavy chain of the antibody. It is
efficiency and ease of removal of the immobilized pro also preferred that the protein is an IgG immunopro
tein due to the immobilization at a specific and constant tein.
site remote from the reactive sites. Another advantage
The exopeptidase enzyme may be a carboxypepti
is the ability to increase the packing density of the in dase, preferably a serine or cysteine carboxypeptidase.
mobilized protein when all molecules are aligned in the 35 The invention is also directed to methods for prepar
same direction and have exposed active sites.
ing a labeled protein. The methods comprise coupling a
The method for use of a bioactive agent bound to a protein and a nucleophile of a labeled amino acid, amino
protein also proceeds in a recognized manner as indi acid derivative, amine or alcohol in a nonneutral me
cated by the bioactive agent and the nature of the pro dium and in the presence of an exopeptidase enzyme.
tein. The action of the protein and bioactive agent coop The label may be fluorescent, nuclear magnetic, phos
erate to cause the effect desired. The protein may act as phorescent, colorimetric, magnetic, electron resonant
a carrier to transport the agent across membranes or to or spectrometric. One particular method according to
cause its absorption into fluids, media or cells. It may the invention comprises (a) coupling a protein and a
also act as an absorption inhibitor to prevent transport nucleophile in a non-neutral medium and in the pres
of the agent across membranes or to prevent its absorp 45 ence of an exopeptidase enzyme to form an adduct, the
tion into fluids, media or cells. It may further act as a nucleophile having a side chain with a distinctive reac
targeting vehicle to direct the agent to selective tissue tive substituent preferably selected from the group con
sites or receptors. The advantage of this method is that sisting of sulfhydryl, hydroxyl, activated hydroxyl,
by leaving the active sites free, the reaction efficiency olefinyl, activated ester, amino, azidyl, hydrazinyl,
and tissue selection are increased.
phosphoramidoyl, boronyl, ferrocenyl, ferro complexes
In sum, the present invention is directed to methods and any mixtures thereof, (b) combining a label and a
for forming a protein bound to an auxiliary substance. linker arm to form a combination, the label having at
One such method comprises the steps of (a) coupling a least one reactive group and the linker arm being a
nucleophile to the protein by catalysis with an exopepti flexible or semi-flexible chain having a specifically reac
dase enzyme to form an adduct, wherein the nucleo 55 tive group that is correlatively reactive with the distinc
phile is an amino acid, amino acid derivative, amine or tive reactive substituent and another functional group
alcohol having a side chain with a distinctive reactive that is reactive toward the reactive group of the label,
substituent, and (b) binding the adduct to the auxiliary and (c) binding the adduct and the combination to form
substance or its combination with a linker arm to form the labeled protein. Another labeling method comprises
the bound protein, the auxiliary substance or combina (a) combining a label and a linker arm to form a combi
tion having a specifically reactive group that is correla nation, the label having at least one combining group,
tively reactive toward the distinctive reactive substitu and the linker arm being a flexible or semi-flexible chain
ent of the adduct. Another method of binding a protein having a specifically reactive group that is or is ren
to an auxiliary substance includes the steps of (a) bind dered nonreactive with the combining group of the
ing a nucleophile to the auxiliary substance or its combi 65 label and an other functional group that is reactive
nation with a linker arm to form an intermediate, toward the combining group of the label, (b) binding
wherein the nucleophile is an amino acid, amino acid the combination and a nucleophile to form an intermedi
derivative, amine or alcohol having a side chain with a ate, the nucleophile having a side chain with a reactive
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substituent that is reactive toward the specifically reac droxyl, activated hydroxyl, amino, activated ester,
tive group of the combination, and (c) coupling a pro olefinyl, azidyl, hydrazinyl, phosphoramidoyl, boronyl
tein and the intermediate in a non-neutral medium and
ferrocenyl, ferro complexes and any mixture thereof.
in the presence of an exopeptidase enzyme to form the
Another method for preparing an immobilized pro
labeled protein. Yet another method for preparing a tein according to the invention comprises (a) combining
labeled protein comprises (a) binding a label and a nu an immobilization support and a linker arm to form a
cleophile to form an intermediate, the nucleophile hav covalently bound combination, the support having at
ing a side chain with a reactive substituent, and the label least one combining group, and the linker arm being a
having a reactive group that is reactive with the reac flexible or semi-flexible chain having a specifically reac
tive substituent of the nucleophile, and (b) coupling a 10 tive group that is or is rendered non-reactive with the
protein and the intermediate in a non-neutral medium combining group and an other functional group that is
and in the presence of an exopeptidase enzyme.
reactive toward the combining group of the support, (b)
The resulting labeled proteins may include a protein binding the combination and a nucleophile to form an
having a labeled nucleophile of an amino acid, amino intermediate, the nucleophile preferably being an amino
acid derivative, amine or alcohol coupled to or substi 15 acid, amino acid derivative, amine or alcohol having a
tuted on its carboxyl terminus. Preferably, the nucleo side chain with a reactive substituent that is reactive
phile is substantially exclusively coupled to or substi toward the specifically reactive group of the combina
tuted on the carboxy terminus. It is preferred that the tion, and (c) coupling the intermediate and a protein in
protein is a monoclonal or polyclonal antibody, and that a nonneutral medium and in the presence of a exopepti
the nucleophile is serine, taurine, or alanine. It is further 20 dase enzyme to form the immobilized protein. Yet an
preferred that the labeled nucleophile is radioactive.
other method comprises the steps of (a) binding a nu
In the protein labeling methods according to the cleophile and an immobilization support to form an
invention, it is preferred that the protein concentration intermediate, the nucleophile preferably being an amino
is about 1 M to about 1 mM, and the enzyme concen acid, amino acid derivative, amine or alcohol having a
tration is from about 1 pM to mM. Under acidic cou 25 side chain with a reactive substituent, and the immobili
pling conditions, it is preferred that the nucleophile is an zation support having at least one specifically reactive
alcohol. Under basic coupling conditions, it is preferred group that is reactive toward the reactive substituent of
that the nucleophile is an amino acid, amino acid deriva the nucleophile, and (b) coupling a protein and the
tive, or amine; that the coupling reaction is conducted intermediate in a non-neutral medium and in the pres
for at least 5 seconds; and that the protein, nucleophile 30 ence of an exopeptidase enzyme to form the immobi
and enzyme are combined in an aqueous mixture. This lized protein.
mixture may be formed by (a) combining the protein
According to any of the methods for preparing an
and the nucleophile to form a mixture, (b) adjusting the immobilized protein of the invention, it is preferred that
pH of the mixture to within a range of about 2.0 to 10.5, the carboxyl terminus of the protein is coupled to the
35 support. The support may be inorganic or organic.
and (c) adding the enzyme to the mixture.
The invention also provides a method for detecting Further, the support may be porous or semi-porous
the presence of an antigen. The method includes the microparticles, microbeads, beads, spheres, gel parti
steps of (a) combining a labeled antibody with a mate cles, fibers, platelets, sheets or particulate material.
rial suspected of containing an antigen to form a com
The invention further provides methods for prepar
plex, the labeled antibody being specifically immunore ing a protein augmented by a bioactive agent. One such
active with the antigen, (b) removing any uncomplexed method comprises (a) coupling a protein and a nucleo
labeled antibody, and (c) measuring the amount of la phile in a non-neutral medium and in the presence of an
beled antibody present in the complex.
exopeptidase enzyme to form an adduct, and (b) binding
The invention further provides methods for prepar the adduct and a bioactive agent to form the augmented
ing an immobilized protein. One such method includes 45 protein, the bioactive agent having at least one specifi
the steps of (a) coupling a protein and a nucleophile in cally reactive group that is correlatively reactive
a non-neutral medium and in the presence of an exopep toward the reactive substituent of the adduct. Another
tidase enzyme to form an adduct, and (b) binding the method comprises the steps of (a) coupling a protein
adduct and an immobilization support to form the im and a nucleophile in a non-neutral medium and in the
mobilized protein, wherein the support has at least one presence of a exopeptidase enzyme to form an adduct,
specifically reactive group that is correlatively reactive and (b) combining a bioactive agent and a linker arm to
toward the distinctive reactive substituent of the ad form covalently bound combination, the bioactive
duct. Another method comprises (a) coupling a protein agent having at least one combining group, and that the
and a nucleophile in a non-neutral medium and in the
arm being a flexible or semi-flexible chain having
presence of a exopeptidase enzyme to form an adduct, 55 alinker
specifically reactive group that is correlatively reac
(b) combining an immobilization support and a linker tive toward the reactive substituent of the adduct and
arm to form a covalently bound combination, wherein an other reactive group that is reactive toward the
the immobilization support has at least one combining combining group of the bioactive agent, and (c) binding
group, and the linker arm is a flexible or semi-flexible the adduct and combination to form the augmented
chain having a specifically reactive group that is correl protein. Preferably, the nucleophile is an amino acid,
atively reactive with the distinctive reactive substituent amino acid derivative, amine or alcohol having a side
of the adduct and another functional group that is reac chain with a distinctive reactive substituent selected
tive toward the combining group of the support, and (c) from the group consisting of sulfhydryl, hydroxyl, acti
binding the adduct and the combination to form the vated hydroxyl, amino, activated ester, olefinyl, azidyl,
immobilized protein. According to either method, the 65 hydrazinyl, phosphoramidoyl, boronyl ferrocenyl,
nucleophile may be an amino acid, amino acid deriva ferro complexes and mixtures thereof,
tive, amine or alcohol having a side chain with a distinc
Another method for preparing a protein augmented
tive reactive substituent, for example, a sulfhydryl, hy by a bioactive agent includes (a) binding a nucleophile
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and a bioactive agent to form an intermediate, the nu
cleophile being an amino acid, amino acid derivative,
amine or alcohol having a side chain with a reactive
substituent, and the bioactive agent having at least one
specifically reactive group that is reactive toward the
reactive substituent of the nucleophile, and (b) coupling
a protein and the intermediate in a non-neutral medium
and in the presence of an exopeptodase enzyme to form
the augmented protein. An alternative method of form
ing an augmented protein involves (a) combining a
bioactive agent and a linker arm to form a covalently
bound combination, the bioactive agent having at least
one combining group, and that the linker arm being a
flexible or semi-flexible chain having a specifically reac
tive group that is correlatively reactive toward the
reactive substituent of the adduct and an other reactive
group that is reactive toward the combining group of
the bioactive agent, and (b) binding a nucleophile and

10

FIG. 1B is a graph of the pH dependence of the in
corporation of serine in an antibody with respect to time
at 25' C.
FIG. 1C is a graph of the pH dependence of the
incorporation of serine in an antibody with respect to
time at 37 C.
FIG. 2 is a graphical representation of the effect of
incubation time on serine incorporation.
10

DETAILED DESCRIPTION OF THE
INVENTION

Until the present invention, a general method for
highly selective, single site attachment of a auxiliary
substance to a protein did not exist. The present meth
15 ods solve this problem by providing precise control of
the protein site to which the auxiliary substance is
bound. This control causes the auxiliary substance to
bind to a specific site on the protein that is as distant
the combination to form an intermediate, the nucleo from the protein functional sites as possible, i.e. the
phile being an amino acid, amino acid derivative, amine carboxyl terminus.
or alcohol having a side chain with a reactive substitu
More specifically, the present invention is based upon
ent that is reactive toward the specifically reactive the discovery that amino acids, amino acid derivatives,
group of the combination, and (c) coupling a protein amines and alcohols can be coupled to the carboxyl
and the intermediate in a non-neutral medium and in the termini of biologically active proteins by a condensation
presence of a exopeptidase enzyme.
25 or transpeptidation reaction under basic, exopeptidase
According to methods for preparing an immobilized catalysis conditions or by a transesterification reaction
protein or for preparing a protein augmented by a bi under acidic exopeptidase catalysis conditions (the pri
oactive agent, it is preferred that the nucleophile is an mary coupling reaction). See J.S. Fruton in "Advances
amino acid, amino acid derivative or amine under basic in Enzymology', A. Meister, ed. Vol. 53, 1982, John
coupling conditions, and an alcohol under acidic cou Wiley & Sons New York, pp. 239-306 for a general
pling conditions.
review of proteinase catalyzed synthesis of peptide
The invention also includes methods for functionally bonds, the disclosure of which is incorporated herein by
reacting a protein by employing an immobilized protein reference. With respect to almost all functional prote
as produced according to the methods of the invention. ins, and especially antibodies, the carboxyl terminus of
Further included are methods for conducting a bioreac 35 the peptide chain or chains occurs within a region of its
tion with a bioactive agent by employing a protein three dimensional structure that is almost always re
carrying a bioactive agent as produced according to the mote from the active site region. In antibodies, for ex
methods of the invention.
ample, this terminus occurs within the constant region
According to the methods of the invention, it is pre that is remote from the active, variable region of the
ferred that the "distinctive reactive substituent' and antibody. Consequently, binding the auxiliary substance
“specifically reactive group' are selected from the fol to the carboxy terminus of the protein provides the
lowing pairs: (a) a sulfhydryl group and a organometal control sought.
lic group, (b) an olefinyl group and a dienyl group, (c)
As described in the foregoing Summary of the Inven
a polar olefinic group and its corresponding monomer tion, the attached substance is bound to the carboxy
or substituted forms thereof, (d) an affinity complexing 45 terminus of the protein through either of two synthetic
compound and its substrate, (e) a pair of hydroborated routes. In the first, the nucleophile is separately coupled
olefinic groups, (f) an aromatic amino group and an to the protein to form an adduct of the protein and
epoxy activated ester or aldehyde group, (g) an azidyl nucleophile. The adduct is then bound to the auxiliary
or hydrazinyl group and an aromatic amino group, (h) substance directly, or is bound indirectly through a
an aromatic alcohol and an activated ester group, and (i) linker arm-auxiliary substance combination.
a hydrazine and a reducing sugar group.
In the second synthetic route, the nucleophile and
It is also preferred according to the methods of the auxiliary substance are directly bound, or indirectly
invention that the linker arm chain is a polymer or

oligomer of amide, ester, carbonate, urethane, ether,
glycidyl, olefin or hydrocarbon groups, or an aliphatic
group of from about 2 to 20 atoms, or an aromatic group
of from about 1 to 5 rings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a graph of the pH dependence of the
incorporation of serine in an antibody with respect to

bound through a linker arm, to form an intermediate.

55

The intermediate is then coupled to the carboxy termi
nus of the protein.
These synthetic routes are depicted in the following
scheme. Both synthetic routes operate in two versions,
which depend upon whether the auxiliary substance is
directly or indirectly bound to the nucleophile.

time at O' C.

Schene
Route
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-continued
Schene

ProCO2H

(protein)

--

X-R

(nucleophile)

with enzyme
ProCOX-R

(adduct)

N SRG-(Link)-(ASub)

-- no-o/
ProCOX-R-SRG-(ASub)

ProCOX-R-SRG-(Link)-(ASub)

ProCOX-R-SRG-(Link)-(ASub)
Route 2

X-R

X-R
--

--

SRG-(ASub)

(nucleophile)

SRG-(Link)-(ASub)

N

/

X-R-SRG-(Link)-(ASub)
--

ProCO2H

(protein)

with enzyme

ProCOX-R-SRG-(Link)-(ASub)

ProCO2H is protein. R-X is the nucleophile, i.e., amino acid or aliphatic
goup. ASub is attached substance. Link is a linker arm. SRG is specifically
reactive group. The letter n is the number 0 and 1. Choice of X, R, SRG
and route depend upon the functional groups of the protein and the

amine wherein R is the side chain and X is the attaching amine or hydroxy
solubilities of the reactants.

Route 1

40

According to route 1, the first step is the primary
coupling reaction to form the adduct of protein and
nucleophile. It is accomplished by exopeptidase cataly
sis under non-neutral conditions.

45

The choice of the particular amino acid, amino acid
derivative, amine or alcohol as the nucleophile in the
first step depends upon the identity of the amino acids of
the protein and upon the distinctive character of the
side chain of the nucleophile. The side chain of the 50
coupled nucleophile acts as the binding site for the
specifically reactive group of the attached substance or
the combination of linker arm-attached substance. It has
a structure that either is non-duplicative of the amino
acids of the protein or is more highly reactive toward 55
the specifically reactive group of the combination or
auxiliary substance than are the amino acid side chains
of the protein. It also is selected to avoid or minimize
direct reaction with these side chains.
This selectivity imposed by the nucleophile side chain
is accomplished by its reactive substituent. This substit
uent may be a sulfhydryl, olefinyl, amino, azidyl, hy
drazinyl, epoxy, hydroxyl, activated hydroxy wherein
the activator is a facile leaving group such as tosyl,

phosphoramidoyl, ferrocenyl, ferro complexes, boronyl
and similar reactive functional groups.
In the second step of route 1, the primary binding
reaction is accomplished by binding the nucleophile
side chain either to the auxiliary substance or to its
combination with the linker arm. In both of these varia
tions, the specifically reactive group of the combination

or auxiliary substance correlates with the reactive sub
stituent of the side chain so that the side chain and auxil

iary substance or combination readily react without
substantially involving other groups of the protein.
To accomplish this selective reactivity of the primary
binding reaction, the reactive substituent and specifi
cally reactive group are correlated as pairs of groups.
Several embodiments of this pair exhibit noncompeti
tive binding which essentially will not involve other
groups of the protein. These include, for example:
(1) a sulfhydryland an organometallic group, prefera

bly an organomercuric group or Alman reagent

which are particularly useful with antibodies be
cause antibodies do not naturally contain free sulf
hydryl groups, i.e. cysteine within or close to their
active sites;
(2) an olefinyl group and a dienyl group, which form

mesyl and benzoyl, an acid group such as carboxyl, 65
a Diels-Alder adduct;
phosphoric or sulfonic, an activated ester such as a
(3) a phosphoramidoyl group and a metaliophos
mixed anhydride, carbodiimido, iminyl amidinyl,
phoramidoyl or metallophosphate group, which
imidazo, pivaloyl ester, neopentyl ester and the like,
form co-ordinate complexes;

13
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(4) an affinity complexing compound and its corre
sponding substrate, e.g. carbonic anhydrase and
sulfanilamide or biotin and avidin, which form

affinity complexes;
(5) a ferrocenyl group or ferro complex and a mag

involve stirred reactors, removal of side products and
slow addition of reagents. A further condition is the

netic material rendered inert to the reaction me

dium, e.g. a teflon-coated iron wire coil, which
form a magnetic couple;
(6) a chelating group and a chelated moiety such as
ethylene diamine tetraacetate and a transition
metal, which form a chelate;
(7) a polar olefinic or substituted olefinic group and
the corresponding monomer, which polymerize by
free-radical means under mild conditions, e.g. N
acryloyl lysine and acrylamide, and form a poly

10

tion is to be maintained so that the chance of undesirable

15

(8) a pair of olefinic groups, which can be hy
droborated and then treated with silver nitrate and

weak base to form the reduced, coupled olefin-ole
(9) a photoreactive arylketo group and a free radical
stabilizing group having a radical-labile C-H
bond; such as benzoylphenylalanine and a benzyl, 25
allyl or arylalkyl group, which can be photolyzed
fin adduct; and

to form an adduct between the keto carbon and the

C-H carbon of the free radical stabilizing group.
Preferably such free radical stabilizing groups as
polyamide, polycinnamide, polystyrene, or fluo

rene containing polymers (supports), porphyrin or
35

reaction of the side chain and attached substance or

combination. These include, for example:

(1) an aromatic amino group and an epoxy, activated
ester or aldehyde group, preferably an aromatic 45
epoxy or aldehyde group, which can be reacted to
form a nitrogen-carbon adduct, and under slightly
acidic conditions to protonate the amine groups of
the protein;
(2) an azidyl or hydrazinyl group and an aromatic 50
amine, which can be reacted by irradiation with
UV light to form a substituted amine, and under
slightly acidic conditions to protonate the amine
groups of the protein;
(3) an aromatic alcohol (e.g. phenolic group) or aro 55
matic amine and an activated ester, which can be

reacted to form an ester or amide respectively, and
under slightly acidic conditions to protonate the
amine groups of the protein; and

(4) a hydrazine and a reducing sugar, which form an
OsazOne.

The conditions and procedures for performing the

binding reactions of the side chain and specifically reac
tive group are known in the art. See for example "Rea 65
gents for Organic Synthesis" by Fieser & Fieser, John
Wiley & Sons, New York, Vol. I-X, 1967-1975, the
disclosure of which is incorporated herein by reference.

maintenance of a minimal concentration of any reactant
that can react with more than one group in the reaction
mixture. For example, a minimum concentration of
auxiliary substance or combination in the binding reac

side reactions of the specifically reactive group with the
protein are minimized.

ner;

fluorescein, (label) and benzyl substituted bioactive
agents are employed at significantly higher concen
trations than the protein coupled to the arylketo
nucleophile so that photolytic addition of the pro
tein to itself is highly disfavored (See J.C. Kauer, et
al., J. Biol. Chenn., 261, 10695 (1986)).
Other embodiments of this pair exhibit competitive
binding relative to the functional groups of the protein
but can be controlled to provide a substantially selective

14

The conditions will generally be approximately ambient
temperatures (0 to 38 C), and dilute to moderate con
centrations of reactants. The procedures will generally

Route 2

According to route 2, the nucleophile and the auxil
iary substance or its combination with linker arm are
first bound by the primary binding reaction to form an
intermediate. This step can be accomplished by employ
ing (1) any of the reactive substituent and specifically

reactive group pairs described above; (2) the combining
group and other functional group pairs described below
for the linker arm, or (3) by any of the known methods
for forming an amide, ester, ether, imino, carbonate,

urethane (carbamate), carbon-carbon, carbon-nitrogen,
sulfur-carbon, sulfur-oxygen-carbon or carbon-oxygen
bond. Methods to form these bonds and the particular
groups formed thereby are known in the art. See, for
example "Chemical Reagents for Protein Modifica
tion", CRC Press Inc., R.L. Lundblad & C.M. Noyes
ed. 1984; "Basic Principles of Organic Chemistry", J.D.
Roberts and M. Caserio, Benjamin Press, 1975, the dis
closures of which are incorporated herein by reference.

Choice of the particular manner of binding the auxil
iary substance or combination to the nucleophile does
not depend upon the structure of the protein according
to this route. Any stable binding group that is appropri
ate for the chemical structures of nucleophile and auxil
iary substance or linker arm combination will suffice
because this binding reaction is not conducted in the
presence of the protein.
The second step of route 2 couples the intermediate

to the protein through the primary coupling reaction of
the nucleophile portion of the intermediate and the

protein carboxy terminus. It is accomplished by exopep

tidase catalysis under non-neutral conditions. The selec
tivity of this reaction suits it as the one to be conducted

in the presence of protein. The scheme of route 2 uti
lizes this feature to best advantage because it places the

primary coupling reaction last in the reaction sequence

thereby eliminating the potential interference from the
primary binding reaction.
The second step of route 2 has some attendant param

eters that primarily are directed to reaction efficiency.
The reactants should have sufficient solubility in the
reaction medium to enable relatively facile coupling to
take place. Generally, this solubility will be preferably
about 0.05 to 2M for the reactants and 1 to 100 LM for
the enzyme. When the solubilities of the reactants of the
coupling reaction are less than this, route 1 is preferen
tially employed.
Specific embodiments of labels, support materials and
bioactive agents that can be coupled to proteins by
synthetic route 2 are shown in Table 1.

5,234,820
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TABLE 1.
Amino Acids for Coupling Labels, Bioactive Agents
and Supports to Antibodies (Potential Applications are
listed along with the chemical names of the Amino Acids)
HOCH2CH(NH2)CO2H
Iodotyrosine
Serine
Taurine
3H, 14C
3H, 14c, 35S

Seyi

Radioactive Label

Radioactive label

H2NCH2CH2PO3H

Radioactive Label

FC6H4CH2CH(NH2)CO2H
Fluorophenylalanine

Aminoethanephosphonic
Acid
*H, 14c, 32p

NMR Label

Radioactive Label

31P. NMR Label

CH2-------CH-CONHC6H4CH2CH(NH2)CO2H
NH

Pt

Cl

/ N

C

Metal Chelate

Platinum for Electron Microscopy
and X-ray Labels
Cobalt for Ratiation Therapy
fluoroescenyl NHCSNH(CH2)4CH(NH2)CO2H

Lysylfluorenscene

Fluoroescent Label

(NO2)2C6H3NH(CH2)4CHONH)CO2H
Bisnitrophenylysine
Fluorescent Label

Antigenic Label

NH

V
CO-NH

Biotin Group for Complex
Attachment to Avidin-Resin or as

Label for Enzymatic Detection

H2C=HCH2NH + CH3CH=CHCH=CHCO2-(attached substance)
Diels-Alder
For Attachment of Resin
or other attached substance

H2C=CHCONHCH2)4CH(NH2)CO2H + H2C=CHCONH-OH or attached substance)
Free Radical Polymerization

Magnetic Process

Linker Arm

There are several reasons why the linker arm version
invention. First, the environment of the carboxyl termi
nus may prevent approach of a large, bulky auxiliary
substance. Second, the auxiliary substance may not

group mentioned above that reacts with the side chain

of routes 1 and 2 would be selected according to the

55

contain functional groups that are specifically reactive

with the side chain of the nucleophile. Third, the linker
arm increases the distance between the auxiliary sub
stance and the protein which can help maintain the

activity of the protein. Fourth, the protein can more
freely adopt a spatial conformation that is appropriate
for its reactivity. Fifth, it will lessen or minimize alter
ation of protein confirmation caused by carrier material
proximity.
65
The structure of the linker arm includes functional

groups at the ends of a flexible to semi-flexible chain.

One of the functional groups is the specifically reactive

of the nucleophile. The other functional group of the
linker arm is chosen to readily react with available
combining groups on the auxiliary substance. Of course,
this pair of groups of the linker arm is selected so that
one does not substantially interfere with the other when
they are used in the binding and combining reactions.
In both synthetic routes, the step to combine linker
arm and attached substance is accomplished before the
binding reaction with the nucleophile. Since protein
and nucleophile are not present during this step, the
kinds of reactions available are numerous. If the com
bining group of the auxiliary substance is an aldehyde
group, the other functional group may be an amine
(Schiff base product), an activated acid such as an
iminocarboxy, carboxyalkoxy or acid halide (amide
product) or epoxy (substituted amine product). If the

5,234,820
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combining group of the auxiliary substance is an hy
droxy group, the other functional group may be an
activated acid or ester (ester product) or activated alkyl
such as a halo alkyl, alkyl tosyl or alkyl mesyl (ester

product). If the combining group of the auxiliary sub

stance is an acid group, the other functional group may
be an amine (amide product) or activated hydroxyl
(ester product). If the combining group of the auxiliary
substance is a chelating agent, the other functional
group may be a bound metal group. Other pairs of reac
tants include water soluble carbodiimide and amino;
N-acyl succinimide and amino; and olefin and diene as
well as those described above under part (3) of the
primary binding reaction for route 2. Of course, the
reverse order of reaction is also possible.
The backbone of the linker arm may be any that

10
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provides a flexible or semi-flexible chain. Included are
polymers and oligomers of amides (peptides), olefins,
esters, carbonates, urethanes, ethers, glycidyl, epoxides

and the like. Also included are alkylene and hydrocar
bon chains. The length of the backbone may be from
about two to about 100 atoms or monomeric units, pref
erably about four to about 20 atoms or monomeric units
in length. Examples of the backbone include hexylenyl,

decylenyl, poly(4-aminobutyric acid), poly(glycyl),
poly(glycylalanyl), poly(4-hydroxybutyric acid), poly
lactones, poly(bisphenol-A-diglycidyl ether) and poly
acrylamide.

proteins are preferred as proteins.
Nucleophile Chosen as an Amino Acid
A wide variety of amino acid nucleophiles can be
used in the present invention. Generally these include
alpha amino acids with neutral, basic or acidic side
chains wherein the side chains may contain the reactive
substituents mentioned above. The choice of amino acid
for labeling antibodies, binding proteins to immobilizing
support, or binding bioactive agents to proteins is gener
ally coordinated with the enzyme and the protein
chosen. Certain enzymes will couple specific amino
acids to the carboxyl termini of proteins. For example,
CPD-Y will generally couple amino acids with neutral
or basic side chains to antibodies. Certain other en
zymes, which utilize cysteine and/or serine at their

enzymatic sites and are derived from plant and micro
bial sources, will couple amino acids with acidic side
chains to proteins.

Furthermore, in order to perform the binding reac

25

tion, the amino acid nucleophile will exhibit a distinc
tive reaction character. This will allow its selective
binding to the auxiliary substance or its combination

with linker arm. The distinctive character results from
the reactive substituent of the side chain of the nucleo

phile as explained above. This reactive substituent may
be a sulfhydryl, hydroxy, activated hydroxyl, phospora
midoyl, hydrazinyl, amino, azidyl, epoxy, acid, boronyl,
activated esters, ferrocentyl, ferro complex or olefinyl

Proteins

The types of proteins (including peptides as small as
two residues) that can be coupled according to the
present invention are active proteins with polypeptide
chains containing reactive carboxyl termini. Examples
of suitable proteins include enzymes, enzyme inhibitors,
hormones including peptide hormones, antibodies, Fab
truncated antibodies, functional proteins, transcriptases,
reading frame proteins, DNA binding proteins and
other biologically active polypeptides.
With respect to labeling, monoclonal or polyclonal
antibodies, antibody light and heavy chains, antibody
fragments, epitopal sites of antibodies, chimeric anti
bodies, CDR antibodies, DNA binding proteins, en

18

proteins (eg. collagen), globular proteins and fibrous

group, mixtures thereof and other functionally reactive
Embodiments of these amino acid nucleophiles in
clude aliphatic amino acids such as monoamino mono
carboxylic acids, e.g., glycine, alanine, valine, norva
line, leucine, isoleucine, and norleucine (useful as radio
active label); hydroxy amino acids such as serine, threo
nine, and homoserine; sulfur-containing amino acids
such as methionine, cystine, cysteine, and taurine (for
linker arm or auxiliary substance binding); diamino
monocarboxylic acids such as orthinine, lysine, and
arginine (for linker arm or auxiliary substance binding);
and monoamino dicarboxylic acids such as aspartic acid
and glutamic acid (for linker arm or auxiliary substance
binding). Also, aromatic amino acids, such as phenylala
nine and tyrosine; heterocyclic amino acids, such as
histidine and tryptophan, and olefinic amino acids such
as 2-amino-2-vinyl acetic acid (for linker arm or auxil
iary substance binding) are included within the group of
amino acids of the present invention.
Additional amino acids are those with the C-terminal
end protected. This includes, for example, amides, ani
lides, hydrazides, esters, and the like.
Preferred classes of amino acid nucleophile include
aliphatic amino acids, hydroxy amino acids, their acti
vated derivatives, phosphoramidoyl amino acids, sul
fur-containing amino acids, diamino monocarboxylic
acids, activated ester amino acids, aromatic amino acids
and heterocyclic amino acids. Especially preferred em
bodiments include serine, alanine, phenylalanine, tau
rine, lysine, arginine, 2-aminopenta-4-enoic acid and
groups.

35

zymes, and reading frame proteins are preferred as pro 45
teins. As used herein, the term "antibody fragments'
includes variable or constant regions of antibody chains,
Fab or F(ab')2 and Fc fragments, light and heavy vari
able chains, epitopal regions of light or heavy antibody
chains, combinations of such regions and chains, and
recombinations of a particular fragment with a comple
mentary fragment isolated from the same antibody or a
different source of antibody, to form, for example, chi
meric human-mouse antibodies carrying human con
stant regions, or altered human antibodies carrying 55

hypervariable segments derived from antibodies from a
differing mammalian source. The antibodies and anti
body fragments are generally useful in the diagnosis of
diseases, disorders, or hereditary dysfunctions. The
antibodies are also generally useful in separation tech 60
niques and for detection of antigenic material. This
includes mammalian immunoglobulin proteins from the
IgA, Igld, IgE, IgM, or IgG class of immunoproteins.
With respect to immobilization, mono or polyclonal
antibodies and enzymes are preferred as proteins.
65
With respect to bioactive agents, mono or polyclonal
antibodies, peptide hormones, histocompatibility prote
ins, polypeptide inhibitors, peptide toxins, structural

cysteine. Also included are carboxyl protected amino

acids, such as amides and esters.

Nucleophile Chosen as an Amine

The amine nucleophile includes any C2 to Co pri
mary amine that has another reactive substituent along
its backbone as described above. Alternatively, it may
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have a simple, nonfunctional side chain in circum
stances where it is also the auxiliary substance. In addi
tion to being a decarboxy analog of the amino acid
nucleophile, the amine nucleophile may also have a side
chain substituted by hydroxyl, sulfhydryl, activated
hydroxyl, epoxy, amino, azidyl, olefinyl, activated es
ter, hydrazinyl, phosphoramidoyl, boronyl, iminyl,
amidinyl, ferrocentyl, ferro complexes or other func
tionally reactive groups. Alternatively, it may have a
simple, nonfunctional side chain in circumstances where
it is also the auxiliary substance.
Nucleophile Chosen as an Alcohol
The alcohol nucleophile includes any C1 to C20 pri

mary alcohol that has another reactive substituent along

20

peptidase A, carboxypeptidase B and metalloproteases,
which perform the condensation reaction only. Certain
other of the serine carboxypeptidase enzymes are capa
ble of attaching amino acids and aliphatic amines having

10
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its backbone. The reactive substituent may be a hy
droxyl, sulfhydryl, activated hydroxyl, epoxy, amino,
azidyl, hydrazinyl, olefinyl, activated ester, phosphora
midoyl, boronyl, iminyl, amidinyl, ferrocentyl, ferro

acidic side chains to the carboxy termini of proteins.
Carboxypeptidase Y is a preferred enzyme for use in
this invention. CPD-Y is an enzyme from yeast fungi
possessing a serine residue in its catalytic site, and is
characterized by its ability to catalyze various reactions
depending on the pH of the reaction mixture. Further
more, CPD-Y is a preferred enzyme for use in the label
ing process of the present invention because it rapidly
transpeptidates.
It is to be understood that the enzyme may be immo
bilized or chemically modified to retain or improve
stability and appropriate enzymatic activity. It is also to
be understood that the enzyme source may be yeast,
animal, vegetable, or microbial. Enzymes produced by
the technique of molecular cloning, either of naturally
occurring enzymes or synthetically produced by muta

complex groups, mixtures thereof or other functionally 20
reactive groups. Alternatively, it may have a simple, tion or recombination, are also included in the inven
nonfunctional side chain in circumstances where it is

tion.

also the auxiliary substance.

Immobilizing Supports
Immobilizing supports useful in the present invention
Labels for the proteins according to the present in are inorganic or organic materials functionalized so that
vention include labeled, or tagged amino acids having a a reaction can occur between the nucleophile or linker
variety of substituents or atoms that possess properties arm and the support. When the former reaction is em
suitable for detection by conventional techniques. Such ployed, the support will be functionalized with a specifi
properties include photoaffinity, magnetism, radioactiv 30 cally reactive group mentioned above. When the latter
ity, fluorescence, enzymatic activity, electron dense reaction is employed, the support will be functionalized
(x-ray), nuclear magnetic resonance, electron spin reso with the combining group for the other functional
nance, antigenicity, and phosphorescence. For example, group mentioned above. In this case also, the reactive
amino acids can be labeled with either C or H atoms. substituent may be chelating ferromagnetic groups. The
Further, the amino acids may be tagged by known fluo 35 immobilizing support then has the appropriate charac
rescent dyes, porphyrins, colorimetric dyes, reactive ter to produce binding. With a ferromagnetic group, the
groups and antigens or enzymatic substrates that permit support may be magnetic wire that is rendered inert to
spectroscopic, photographic or radiometric detection. the reaction medium eg. with teflon. Passing a current
See E.T. Koh, et al., Biotechniques, 7,596 et seq. (1989); through the wire will establish the magnetism needed to
S. Borman, "Bioconjugate Chemistry Attracts Grow 40 cause binding. Alternatively, a magnet external to the
ing Interest” in the May 8, 1989 issue of "Chemical and system (i.e. outside the chromatographic medium) can
Engineering News' at p. 25 et seq., the disclosures of be used to cause binding to the support. With the chelat
which are incorporated herein by reference.
ing group, the support may be an immobilized metal or
other chelate.
Enzymes
45
The support may be a porous or semiporous solid.
Enzymes capable of coupling the nucleophile to the Preferably, it is biologically inert and insoluble. Materi
protein are exopeptidases, i.e., enzymes capable of act als that may be used as supports include fibers, sheets,
ing specifically at the carboxyl terminal end of peptide microspheres, particles, microparticles, beads, micro
chains. See J.S. Fruton In "Advances in Enzymology', beads, platelets, membranes, and the like.
in the chapter entitled Reagents for Protein Modifica
The surface of the immobilizing support of the pres
tion as cited above. They form or transform peptide ent invention is preferably porous. The use of sub
bonds and are relatively stable under the reaction condi stances having a porous surface, such as substantially
tions used.
spherical polymeric beads or microspheres of agarose
Carboxypeptidase enzymes are generally known to allows large surface areas for the attachment of protein
cleave the C-terminal peptide bond in polypeptides. 55 at high density. A surface is considered porous where
They exhibit alternative enzymatic activities that are the size of the majority of the pores in the material is
pH-dependent. For example, transpeptidation, transes sufficiently large so as to allow the migration of the
terification and condensation products can be formed protein into the interior of the spheres. The size and
by the pH dependent action of carboxypeptidase Y.
shape of the support may be varied widely, depending
Preferred carboxypeptidases according to the inven on the particular protein and its intended use.
tion include serine and cysteine (eg. hydroxy and thiol)
The immobilizing supports include a wide variety of
carboxypeptidases. Certain of the serine and cysteine substances. The choice of support, however, depends
enzymes are capable of attaching amino acids and ali upon the choice of the nucleophilic and/or linker arm as
phatic amines with neutral or basic side chains to the well as on the intended use of the immobilized protein.
carboxy termini of proteins. Examples of these enzymes 65 The coupling reactions, nucleophile, specifically reac
include carboxypeptidase Y (CPD-Y), penicillocarbox tive group and reactive group all are compatible as
ypeptidase S-1 and S-2, carboxypeptidase C and CN, described above. In particular, the support is chosen
malt carboxypeptidase I and II, phaseolin; and carboxy such that the nucleophile will readily couple to the
Labels

25
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support or support-linker arm combination in prefer
ence to any other reactive sites on the protein. For
example, cysteine may be used as the amino acid nucleo
phile to couple with a protein with no sulfhydryl groups
eg. an antibody. A support or support-linker arm specif.
ically reactive group is chosen that would react with
the sulfhydryl moiety, for example, an organometallic
group such as an organo mercury compound. Alterna
tively, 2-amino-hex-4-enoic acid may be the amino acid
nucleophile, and a specifically reactive group for the
support may be one that would specifically react with
the unsaturated side chain, as for example through a

ture, reactant concentrations, enzyme concentration

and incubation time.

10

Diels Alder reaction. Another alternative is the choice

of a photoaffinity label such as N-hydroxy succinimi
dyl-4-azidosalicylic acid side chain, and an arylamine as
the specifically reactive group on the attached sub
stance. This salicylic side chain is to be coupled to the
epsilon amino group of a lysine before the photo addi
tion so that it will not be reactive with the amino groups
of the protein. Photoreaction under, for example, u.v.
light, will accomplish the desired photo binding reac
tion. Moreover, if a linker arm is used, available groups
on the support act as the reactive group. The other
functional group of the linker arm is appropriately

chosen to bind with the reactive group.
Bioactive Agents

22

the primary coupling reaction to antibody protein, these
conditions generally involve control of pH, tempera
The conditions for condensation and transpeptidation
are basic which also disfavors peptide cleavage by hy
drolysis. They are within a pH range in which the amine
group of the nucleophile is not protonated, i.e., it is in
the free base form. Typically, this range is about pH 8.5
to 11. The selection of condensation over transpeptida
tion is made kinetically in that transpeptidation is com
pleted quickly while condensation occurs slowly. In
particular, transpeptidation occurs between 5 seconds
and 1.4 hours while condensation occurs between 2 and

15 24 hours.
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Included within the invention is a method for attach

Transesterification occurs under moderately acidic
conditions which disfavor hydrolysis. Preferably the
pH is less than about 6 and greater than about 3. A high
molar concentration of the alcohol nucleophile is also
important for transesterification.
The reaction temperature is the functional range of
the enzyme, preferably up to about 40' C.
The concentrations of the reactants and enzyme are
adjusted to provide optimum results. Generally, the
highest possible concentrations of enzyme nucleophile
and protein are used that coincide with an appreciable
primary coupling reaction rate. Preferably, the protein
is present at a concentration of from about 1 M to
about 1M, especially up to about 1 mM when the pro
tein is an antibody. The nucleophile or intermediate
incorporating the nucleophile is preferably present at a
concentration of at least 0.05 molar and especially a
concentration of from about 0.1 to 2 molar. The enzyme
is preferably present at a concentration of about 1 pM to
1 mM.
The incubation time (reaction time) of the protein and
the nucleophile is from about 0.2 to 10 hours, preferably
from 1.0 to 8 hours for condensation while for transpep

ment of a bioactive agent to a protein at a site remote
from the active site. These bioactive agents can be car
ried or transported by the protein to a site where they
can perform a desired reaction.
The bioactive (biologically active) agent includes
physiologically or pharmacologically active substances
that act locally or systemically in the body. Examples of 35
biologically active agents include peptide drugs, protein
drugs, desensitizing agents, antigens, vaccines, anti
infectives, antibiotics, antimicrobials, antiallergenics,
steroidal anti-inflammatory agents, decongestants, miot
ics, anticholinergics, sympathomimetics, sedatives, hyp tidation or transesterification, it is from about 30 sec
notics, psychic energizers, tranquilizers, androgenic onds to about 1.5 hours.
steroids, estrogens, progestational agents, humoral
Specific Embodiments, Antibody Protein
agents, prostaglandins, analgesics, antispasmodics, anti
The pH of the reaction between an antibody and
malarials, antihistamines, cardioactive agents, nonste
roidal anti-inflammatory agents, antiparkinsonian 45 nucleophile determines the dominant enzymatic activity
agents, antihypertensive agents, B-adrenergic blocking exhibited by the carboxypeptidase enzymes. Different

agents, nutritional agents, metal compounds, anti-can
cer compounds such as fluorinated nucleotides, nucleo
tide analogs, cytosine arabinocide, 5-fluorouracil, ricin
A, tetanus toxin, cyclic therapeutic peptides such as
anamycin, erythromycin, cyclosporin, AZT, and alka
loids. Also, various forms of the biologically active
agents may be used. Forms such as uncharged mole

cules, molecular complexes, salts, ethers, esters, and
The bioactive agents are functionalized to carry spe
cifically reactive groups for coupling to the nucleophile
directly. Alternatively, appropriate available combining
amides are included.

groups on the bioactive agent can be reacted with the
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other functional group on a linker arm. Preferably, this
functionalization will be accomplished with a group
already present within the agent.
Conditions for Primary Couplinq Reaction
The conditions for the primary coupling reaction 65
efficiently favor condensation, transpeptidation or
transesterification over peptide cleavage. As can be
seen from the following discussion of the application of

reaction courses are possible at different pH values. The
incorporation of a nucleophile by condensation, tran
speptidation or transesterification depends upon which
reaction course dominates in the incubation mixture.
At neutral pH values, hydrolysis of peptide bonds
(peptidase activity) is generally considered to be the
dominant activity. As the pH increases, the hydrolysis
activity decreases and the condensation and transpepti
dation reactions become the prominent activities of the
enzyme. When the pH is maintained at a level that pro
vides the free base form of the nucleophile, typically
from about 8.5 to 11.0, preferably 9.5, the transpeptida
tion and condensation reaction are favored with the

former being kinetically favored (i.e. happens fast).
Typically, the transpeptidation reaction is preferred
over condensation because it occurs rapidly in about 30
seconds to about 1 hour. When the pH is low such as 3.0
to 6.0 and the molar concentration of alcohol nucleo

phile is high, transesterification is favored. This reaction
cleaves the C-terminal amino acid residue of the protein
and substitutes the alcohol nucleophile by enzyme dis
placement.
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In several studies, the pH dependence of amino acid monoclonal antibody and 114 percent for the polyclonal
nucleophile addition by condensation with an antibody antibody compared to the unlabeled controls. These
was examined and the details are described in the foll
values are an average of four determinations. The slight
lowing examples section. The results of these studies, as increases found for the labeled antibodies over the con
depicted in FIG. 1, show that nucleophile incorporation 5
are due to experimental errors and are not signifi
is higher at higher temperatures and at higher values of trols
cant.
These results show no significant loss of antigen
pH. At a pH of 7.5, the nucleophile incorporation was binding
as a result of label attachment.
observed to increase initially, followed by a decrease in
Similar
reaction conditions of temperature, pH, and
incorporation and then an additional increase. The first
can be established for protein incorpora
incorporation is due to transpeptidation. The decrease O concentrations
tion
of
any
of
the
amino acid or amine nucleophiles or
in incorporation is due to partial loss of the incorpo intermediates as mentioned
above.
rated nucleophile by the disfavored hydrolysis reaction.
The second incorporation is due to the slower addition
Demonstration of Attachment
of the nucleophile by condensation.
The effect caused by variation of the concentration of 15 The results of some experiments wherein other amino
acids were used as radioactive labels are shown in Table

the reactants in the incubation mixture was also studied

and the results are shown in Table 2. As generally indi
cated above, concentration directly affects rate and
amount of incorporation. The details of the study are
provided in the following examples section.

3. The condensation reactions were carried out gener
ally as described in Example 9 and assayed for label
incorporation as described in Example 3. The concen
20

TABLE 2
Effect on Condensation Reaction
of Variation of Incubation Conditions
SER/

Time?

Abb

Serb

CPD-Yc

8

4.1

230

20

3.3

Antibody Conc.

12.7
8.8
2.3
12.3
12.3
12.3
10.5
0.8
.8
7.7

234
232
O
110
220
330
122
112
20
11

20
20
20
20
20
20
5
11
6
20

4.7
1.2
0.16
0.14
1.34
1.68
0.14
0.15
1.6
2.4

Varied

7.7

175

20

4.2.

30% glycerol

10.5

78

20

0.4

F1-nonoclonal

16.9

F1-polyclonal

(hrs) (mg/ml)
9

11.5

8
27

(mM)

(im)

11.1
78
20
Time of labeling incubation at 37 C., pH 9.5.

Abd

Ratio Comments
Serine Conc.
Varied

concentration of the stock solution used. The values of

label incorporation are given as label incorporated per

25

30

35

8.7
14.6
8.8

Label
(mM)
188
44
232

CPD-Ye Label/Abd Labele
(uM)
Ratio Type
20
20
20

0.5
1.2
1.2

Taurine
Alanine
Serine

Time of labeling incubation at 37' C., pH 9.5.

Calculated from concentration of stock solution.

Measurement made or change from standard method (see text for details).

acid between the carboxy termini of heavy and light

interaction.

Abb
(mg/ml)

Molar ratio.
Amino acid used for labeling reaction.

similar results.

antigen-binding region. Therefore, little effect, if any,

Time
(hrs)

Measured concentration in incubation mixture (Ab = antibody).

a single representative experiment. Each experiment was repeated several times with

on the function of the antibody is noted as a result of this

Condensation to Attach Nucleophile
8.5
8.5
8.5

Measured concentration in incubation mixture (Ab = antibody).
Molar ratio, determined as described in methods section. The data shows results of 40

this reaction to a certain extent, it is not located near the

which was incubated under the same conditions with
TABLE 3

Calculated from concentration of stock solution.

The distribution of the nucleophile (labeled amino)
chains of the antibody was also investigates, and the
details are given in Example 4. The results indicate that
the labeled amino acid is preferentially incorporated
into the heavy chain. At least about 70 percent of the
incorporated nucleophile is located on the heavy chain.
Generally, the L-isomers of amino acids are incorpo
rated by this method, with incorporation occurring
substantially completely at the carboxyl termini of the
heavy chains of antibodies.
Although the light chain of the antibody is labeled by

antibody molecule above the value of the control,

out the addition of enzyme.

CPD-Y Conc.
Varied

No Cosolvent

trations of antibody and amino acid shown in Table 3
represent actual measured concentrations. The concen
tration of carboxypeptidase Y is calculated from the

Although some quantitative variation in the amount

of label incorporation was observed in duplicate experi
ments conditions, this was within experimental error.
The variation was probably due to the difficulty of the
separation required for the accurate assessment of the
label incorporation. High concentrations of unbound
label were essentially completely and rapidly separated
from the relatively small quantities of antibody. Some
Small amount of label, however, apparently remained at
times, causing quantitative fluctuations in measured
label incorporation. For this reason, it was necessary to
include a control sample lacking carboxypeptidase Y
for each determination. As an added precaution, the

trailing portion of the antibody peak was not included in
the quantitation.
55

As shown in Table 3, the enzyme incorporates ala
nine to about the same degree as serine. The enzyme
was also found to incorporate taurine, an amino acid not
usually found in proteins. The incorporation of taurine
was found to be somewhat limited by the solubility of
the free amino acid, however.
This method of binding an antibody to a nucleophile
provides a means of immobilizing, labeling or augment
ing antibodies without loss of antigen-binding capacity.
This is due to the primary coupling reaction of the

The antigen-binding capacity of the labeled antibod
ies as compared to that of the unlabeled antibodies was
also studied. (See Examples 5 and 6.) For the anti
asparagine synthetase antibodies the average binding
capacity was determined to be 100.1 percent of the
binding capacity with 0.6 serines incorporated per anti 65 nucleophile with the antibody by condensation, tran
body. The anti-Flantibodies labeled as in Table 2 were speptidation or transesterification.
also assayed to determine their binding capacity. The
Various nucleophiles can be bound to other func
binding capacity was found to be 105 percent for the tional proteins using similar experimental parameters.
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The amino acid or amine nucleophile, enzyme, protein,

and bioactive agent, label or immobilizing support,
however, are generally chosen so as to enhance specific
binding and reduce nonspecific binding. In this way, the
bioactive agent, label or immobilizing support can be
bound to a protein remote from its functional site.
The invention will be further characterized by the
following examples. These examples are not meant to
limit the scope of the invention that has been set forth in
the foregoing description. Variation within the con
cepts of the invention are apparent to those skilled in the
art.
Examples 1-8 are standard methods for condensation,
transpeptidation and transesterification. Example 9
demonstrates condensation. Examples 10 and 11 dem
onstrate transpeptidation. Examples 12 and 13 demon
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(pH 6.8). This diluted sample was counted in a Beckman
LS-100 liquid scintillation counter (Beckman Instru
ments, Fullerton, CA) with 10.0 ml 3a70b scintillation
fluid (Research Products, Elkgrove, IL). The amino

acid concentration of the stock amino acid solution was

10

15

strate transesterification.

determined on a known volume by assay of the amino
groups with the ninhydrin assay; see S. Moore et al., J.
Biol Chem, 157, 367 (1948). A standard solution was
prepared for this assay by dissolving glycine in water at
0' C. to obtain a saturated solution. The liquid was
separated from any undissolved solid glycine, warmed
to room temperature, and used as a standard. The con
centration of the standard was assumed to be 1.89 M;
see J. B. Dalton et al., J. Biol. Chem, 103, 549 (1933).

From these measurements, the quenched value of
CPM/mmole was calculated and used in subsequent

calculations.

EXAMPLE

EXAMPLE 3

Antibody Preparation
20
Anti-asparagine synthetase monoclonal antibodies
and anti-F1 ATPase monoclonal and polyclonal anti
bodies were obtained from laboratory stocks. Mono
clonal antibody stocks were obtained in the form of
mouse Ascites tumor fluids and polyclonal antibody 25

LABEL NCORPORATIONASSAYS

The unbound amino acids were separated from the
antibody by gel filtration HPLC. A 20 ul sample of the
reaction mixture after incubation was applied to a GPC
300 gel filtration column (Synchrom, Linden, In) and
stocks were obtained from rabbit serum. Antibodies
eluted with 0.1 M sodium phosphate (pH 6.8). The
from either source were purified by addition of solid HPLC system employed for this purpose consisted of a
ammonium sulfate to a concentration of 50% of the
dual pump gradient system and a variable wavelength
saturation level. The precipitated protein was collected UV monitor produced by ChemResearch (ISCO, Lin
by centrifugation and dissolved in a minimal amount of 30 coln, NE). The absorbance peak, monitored at 280 nm,
10 mM Tris-HCl (Tris, tris(hydroxymethyl)aminome corresponding to the antibody was collected. In order
thane(pH 7.5). The preparation was then subjected to a to ensure that complete removal of the unbound amino
second ammonium sulfate treatment until a 50% satura
acid from the antibody, only the first of the absor
tion level was reached. The precipitate was then col bance peak was collected. The collected antibody solu
lected by centrifugation. The purified antibodies were
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dissolved in a minimal amount of water and dialyzed for

The antibody concentration in the collected solution
was determined by measurement of the absorbance at

18 to 24 hours against 10 mM sodium bicarbonate at 4
C. This dialysis step was necessary to remove the resid
ual ammonium sulfate that was found to inhibit the
activity of carboxypeptidase Y. The purified antibodies
were stored in aliquots at -20' C. until needed.

Unless otherwise noted, these three antibodies were

used in each of the following examples. The term "anti
body' as used herein means anti-asparaginine synthe
tase monoclonal antibody, and anti-Fl ATPase mono
and polyclonal antibodies.

45

EXAMPLE 2
LABEL PREPARATION

Serine was used initially as H-serine and in latter
experiments 1'C-serine was used. All other amino acids
used were H-amino acids. Radioactive amino acids
were purchased from Amersham (Arlington Heights,
IL). Unlabeled serine was from Fluka (Ronkonoma,
NY). Radioactive amino acids were diluted with unla 55
beled amino acid to, a specific activity of 0.5 to 2 mCi
per millinole. The diluted amino acid was then purified
by repeated precipitation with ethanol at -20' C.
These precipitation steps were required to reduce non
specific binding of the amino acid to the antibodies. The
anino acid was stored as an aqueous solution at 4 C.
The specific activity of the diluted, purified amino

acid was determined as follows, and used in subsequent
calculations of label incorporation. The quenched, de
tectible radioactivity was determined under conditions
identical to those used in the measurement of label in

corporation. A known volume of the amino acid solu
tion was diluted to 1.0 ml with 0.1 M sodium phosphate

tion was diluted to 1 ml with the elution buffer.

65

280 nm, assuming a standard absorbance of 1.46 absor
bance units/mg. The incorporated amino acid was de
termined by counting 1.0 ml of the collected antibody
solution using 10 ml 3a70b liquid scintillation fluid. The
amount of label incorporated was calculated using the
corrected specific activity for the amino acid described
above. The molar concentration of the antibody was
calculated assuming a molecular weight of 150,000; see
I. Roitt et al., Inmunology, C. V. Mosby Co., St. Louis,
p. 5.3 (1985). The reported label incorporation is the
difference between the values obtained for the samples
with and without carboxypeptidase Y. The results of

the label incorporation are discussed in the foregoing

specific embodiments section in conjunction with FIG.
2.

EXAMPLE 4

ANTIBODY CHAIN SEPARATION

This example shows the specificity of nucleophile

coupling to the heavy chain of an antibody as discussed
in the foregoing specific embodiments section.
Separation of the heavy and light chains of the anti
body was performed on both labeled and control (unla
beled) antibodies. The samples were labeled as de
scribed above. Following the incubation, the antibodies
were precipitated by addition of ammonium sulfate to a
concentration of 50% of saturation. The precipitate was
collected by centrifugation and the pellet was dissolved
in a denaturing buffer (pH 6.8) consisting of 100 mM
sodium sulfate, 2 M urea, 2% sodium lauryl sulfate
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(SDS), 1% B-mercaptoethanol, and 25 mM 4-morpho
line ethanesulfonic acid (MES). The sample was incu
bated at 100' C. for 5 minutes to ensure complete dena
turation of the protein. The antibody chains were sepa
rated by gel filtration HPLC using an Altex TSK-125
column (Biorad, Richmond, CA) equilibrated with the
denaturing buffer. The effluent was monitored at 280
nm. The peaks corresponding to the heavy and light
chains of the antibody were collected separately. The
collected samples were diluted to 1.2 ml with the dena
turing buffer.
The amount of amino acid incorporated into each
chain was determined by counting 1.0 ml of each sam
ple with 10 ml 3a70b liquid scintillation fluid. Due to
interference of the denaturing buffer components the
amount of protein in each sample could not be deter
mined by the methods used above or by other com
monly employed methods. An assay developed for this
purpose consisted of adding 25 ul of 30% acrylamide,
0.8% bioacrylamide, to 50 ul of the sample to be as
sayed. The mixture was polymerized by addition of 1.5

added and incubation was continued for an additional 2

O

15

ul 1 10% ammonium persulfate and 1 ul N,N,N',N'
tetramethylethylenediamine. The interfering buffer
components were separated from the solidified sample
by washing with 2 aliquots (2ml) 10% trichloroacetic
acid, 3 aliquots (2ml) 10% acetic acid and 3 aliquots
(2ml) 5% methanol, 7.5% acetic acid. The protein was
stained with Coomassie Blue R-250 (Commission on
Biological Stains Number 42660). Following extensive
washing with 30% methanol, 7.5% acetic acid to re

identical manner.

calculated from these Glu/Gln ratios. The results gen
erally indicate that the capacity of antibody with cou
pled nucleophile is the same as free antibody. See the
discussion at pages 30 and 31.

EXAMPLE 5

ANTI-F1 ATPASE ANTIBODY
IMMUNOPRECIPITATION

This example shows the same effect illustrated in
Example 6.

Both monoclonal and polyclonal antibodies, labeled
sayed by immunoprecipitation to determine their capac
ity to bind antigen. An aliquot of the incubation mixture
was assayed to determine the extent of label incorpora
as described above and unlabeled controls, were as

tion. The remainder of the incubation mixture (80 ul)

ANT-ASPARAGINE SYNTHETASE
ANTIBODY IMMUNOPRECIPITATION

This example shows that the attachment of the nu SO
cleophile does not affect the antigen binding capacity of
the antibody as discussed in the foregoing specific en

bodiments section.

Antibodies, both labeled as described above and con

EXAMPLE 6
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The measured protein content and amino acid incor
poration for each chain were used to calculate the label
incorporation per polypeptide chain. In these calcula
tions, the molecular weights of the heavy and light
chains were taken to be 50,000 and 25,000, respectively;
see I. Roitt et al., vide supra. The results based upon the
data obtained (not shown) are discussed in the forego
ing specific embodiments section and indicate at least a
70% incorporation in the heavy chain.
45

trols, were assayed by immunoprecipitation to deter
mine their capacity to bind antigen. An aliquot of the
incubation mixture was assayed to determine the extent
of label incorporation. The remainder of the incubation
mixture (80 ul ) was added to 420 ul of a pancreas
extract containing asparagine synthetase; see C. A.
Luehret al., J. Biochem. Biophys. Methods, 3, 151 (1980).
The pH of the mixture was adjusted to 7.5. Crude pro
tein A extract (Sigma Chemical Co., St. Louis, MO)
was washed twice by centrifuging the solution and
suspending the pellet in 50 mM Tris-HCl (pH 7.5). This
washed extract was suspended in 5 times its original
volume of 50 mM Tris-HCl (pH 7.5). After incubation
of the antibody with the pancreas extract for 18 hours at

hours. The mixture was then centrifuged to collect the
Protein A/antibody/Asparagine Synthetase complex.
The pellet was washed twice with 50 mM Tris-HCl (pH
7.5) and then incubated for 2 hours with 200 all of an
assay solution (pH 7.5) containing 100 mM Tris-HCl, 10
mM MgCl2, 10 mM ATP, and 10 mM glutamine. The
solid material was removed by centrifugation and the
resulting solution was stored at -20 C. for amino acid
analysis.
Amino acid analysis was accomplished by HPLC
separation of the amino acids following derivitization
with B-mercaptoethanol and o-phthaldialdehyde; see S.
Unnithan et al., Anal. Biochem, 136, 195 (1984). The
HPLC system used consisted of a dual pump gradient
Beckman HPLC system with a Dupont model 836 fluo
rescence detector (E.I.Dupont, Des Plains, IL) and
Integrator (Spectra-Physics, Santa Clara, CA). The
column used was a Rainin Microsorb Cl reversed phase
column (Rainin Instruments, Woburn, MA). The bind
ing capacity of the antibodies was assessed by measure
ment of the hydrolysis of glutamine to glutamate by the
asparagine synthetase bound to the Protein A/antibody
complex. The activity of the bound enzyme was deter
mined by the ratio of the integrated areas of the gluta
mate and glutamine peaks. The percent activity for the
labeled antibodies relative to the unlabeled controls was

move unbound dye, the bound dye was eluted by incu
bation with SDS, sodium bicarbonate, and methanol.
The absorbance of the eluted dye was measured and the

protein content of the sample was determined by com
parison with standard protein solutions assayed in an
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37 C, 1 ml of crude, washed protein A extract was
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was added 420 ul of a 0.2 mg/ml solution of purified
bovine F1-ATPase; see A. F. Knowles et al., J. Biol.
Chem, 247, 6617 (1972). The pH of the reaction mixture
was adjusted to 7.5. Crude protein A extract was
washed twice by centrifuging the solution and suspend
ing the pellet in 50 mM Tris-HCl (pH 7.5). This washed
extract was suspended in 5 times its original volume of
50 mM Tris-HCl (pH 7.5). After incubation of the anti
body with the pancreas extract for 18 hours at 37 C., 1
ml of crude, washed protein A extract was added and
incubation was continued for an additional 2 hours. The

mixture was then centrifuged to collect the Protein
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A/antibody/Fil-ATPase complex. The pellet was
washed twice with 50 mM Tris-HCl (pH 7.5) and then
incubated for 2 hours with 100 pull of an assay solution
(pH 8.0) consisting of 50 mM N-tris(hydroxymethyl)methylglycine (Tricine), 5 mM MgCl2, and 5 mM
ATP. The solid material was removed by centrifugation
and the resulting solution was stored at -20 C. for
analysis. An additional control lacking antibodies was

treated similarly.
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ATPase activity was determined by measurement of
the released phosphate; see S. Unnithan et al., vide

30
EXAMPLE 9

STANDARD CONDITIONS FOR

supra. The bound enzyme was assessed by the produc
tion of inorganic phosphate above the value given by 5 ANTIBODY LABELING (CONDENSATION)
the control which lacked antibody. The percentage of
The following conditions and methods for label in
binding capacity of the labeled versus unlabeled anti corporation
by condensation were used for all runs
bodies was calculated as the ratio of the labeled to the
unless otherwise indicated. A mixture of the antibody
unlabeled activities. The results are discussed in the
and amino acid stock solutions was made and diluted
O with water to the desired concentrations. The pH of this
specific embodiments section at pages 30 and 31.
solution was measured with pH indicator paper (Fisher
EXAMPLE 7
Chemical, Springfield, NJ) and adjusted to 9.5 with 0.5
STABILITY OF LABELED ANTIBODIES
M. sodium From this solution a 4 ul portion was re
moved and diluted to 1.0 ml with 0.1 M sodium phos
The stability of the incorporated label under different 15 phate
(pH 6.8). The absorbance of this solution was
storage conditions was also determined. For this experi measured
at 280 nm using a Beckman DU-50 spectro
ment, label incorporation was assayed on an aliquot of photometer.
The concentration of the antibody in the
the incubation mixture. The antibodies in the remainder solution was calculated assuming a standard absorbance
of the sample were precipitated with ammonium sulfate of 1.46 absorbance units per mg of antibody; see A.
and dissolved in water. An aliquot was stored at 4' C. 20 Good et al., in Selected Methods in Cellular Immunology,
and another at -20' C. for 8 days. Following the stor Mishell & Shiigi eds., W. H. Freeman & Co., San Fran
age period the incorporated label in these samples was cisco, p. 284 (1980). The concentration of the amino
determined and compared to the first sample. The re acid in the incubation mixture was determined by
counting a small sample of the diluted mixture follow
sults are shown in Table 4.
25

ing further dilution to 1.0 ml with 0.1 M sodium phos
phate (pH 6.8). The amino acid concentration was cal
culated from the counts present using the corrected

TABLE 4

Label Stability
Conditions
t=0

Ser/Abb

% of t = 0

0.55

100

specific activity determined previously and correcting
for both dilutions, as well as the 5% dilution described

below.

8 days, 4' C.
0.63
116
8 days, -20' C.
0.49
88
Storage conditions following labeling incubation at 37' C. and pH 9.5.

The remainder of the undiluted mixture was divided

Molar ratio, determined as described in methods section, average of two determina

tons.

Average percent gain or loss of activity compared to no incubation following 35
labelling incubation.

EXAMPLE 8

SPECIFICITY OF INCORPORATION

40

In order to verify that the incorporation is due to
catalysis by the enzyme, L-serine at different concentra
tions and D,L-serine were incorporated by the standard

into two equal parts. To one of these portions was
added the carboxypeptidase Y (affinity purified, E.C.
3.4.16.4, free from endoproteinase contamination) stock
solution (24.3 mg-m/1) at 5 ul per 100 ul of mixture.
The other portion served as a control and was diluted
similarly with water. Once these two solutions were
prepared, they were incubated in a 37' C. water bath for
approximately 8 hours. The samples were then removed
from the water bath and either analyzed immediately or
frozen and used as soon as possible. The results of the
variation in concentration of the label are provided in
foregoing Table 2 and discussed in conjunction there

method. These results are shown in Table 5. The incor 45 with.

poration of D,L-serine is comparable to incorporation
of L-serine at half the concentration of the D,L-serine.

If can be explained by the incorporation of only the
L-isoner. This stereospecificity has been shown for
carboxypeptidase Yunder other conditions; see R. Hya 50
shi et al., J. Biochem, 77, 69 (1975). Nonspecific absorp
tion or other nonenzymatic means of attachment which
might occur under these conditions would be expected
to incorporate both isomers.
55
TABLE 5

Stereospecificity
Time

Abb

Serb

CPD-Y

SER/Abd

(hrs)

(mg/ml)

(nM)

(tM)

Ratio

Comments

8

7.9
10.1
8.1

198
26
177

20
20
20

1.7
0.9
0.5

L-herine
L-serine
D,L-serine

Time of labelling incubation at 37 C. pH 9.5.

Measured concentration in incubation mixture.
Calculated from concentration of Stock solution.

Molar ratio, determined as described in methods section.
Label used.

EXAMPLE 10
TRANSPEPTIDATION WITH A
TETRAPEPTIDE MODEL

This example illustrates the synthesis of the tetrapep
tide Benzoyl-Thr-Val-Ser-(14C)Ser from Benxoyl-Thr
Val-Ser-Ser. About 5 to 10 mM of Benzoyl-Thr-Val
Ser-Ser (BTVSS) may be dissolved in 2 ml of 50 nM
sodium carbonate buffer (pH 9.5) containing 1 mM
EDTA and 0.25 M 14-C-serine. The reaction may be
initiated by the addition of 5 uM carboxypeptidase Y
enzyme. At preset time intervals, the reaction may be
sampled by removing 0.2 ml aliquots and diluting with
0.2 ml of acetonitrile, then adding 0.1 ml of 0.12 M
60 acetic acid.
The samples may then be subjected to high pressure
liquid chromatography (HPLC) using a reverse phase
C-18 column developed with a linear gradient con
structed from two solvents. A first solvent (A) can be
65 95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5
and the second (B) can be 60% acetonitrile. A gradient
can be developed over a 30 min time period and can be
initiated by mixing solvents A and B at the proportions
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of 1 part A and 0 parts B and ended with 40 parts A and
60 parts B. The flow rate can be maintained at 1.0ml per
min. The peptide should elute and be free of serine and
BTVS (hydrolyzed BTVSS).
Separate amino acid analyses of the HPLC fraction
should show the peptide to contain one residue each of
Thr, Val and two residues of Ser. The specific activity
of both the serine recovered from amino acid analysis
and that of the peptide should be the same on a molar

basis.

EXAMPLE 11
TRANSPEPTIDATION WITH A
TETRAPEPTIDE MODEL

This example illustrates the synthesis of the tetrapep
tide Benzoyl-Gly-Ala-Pro-Phe-NH: from Benzoyl-Gly
Ala-Pro-Ala. About 10 ul of 100 mM of Benzoyl-Gly
Ala-Pro-Ala-OH (BGAPA) in dimethyl phthalate

32

ing 0.2 ml aliquots and diluting with 0.2 ml of acetoni

O

15

trile, then adding 0.1 ml of 0.12 Macetic acid.
The samples may then be subjected to high pressure
liquid chromatography (HPLC) using a reverse phase
C-18 column developed with a linear gradient con
structed from two solvents. A first solvent (A) can be
95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5
and the second (B) can be 60% acetonitrile. A gradient
can be developed over a 30 min time period and can be
initiated by mixing solvents A and B at the proportions
of 1 part A and 0 parts B and ended with 40 parts A and
60 parts B. The flow rate can be maintained at 1.0 ml per
min. The Nor-Mab-Ser should elute and be free of ser
ine and Mab. Separate amino acid analysis should show
the Nor-Mab-Ser to contain one residue of Ser. The

specific activity of both the serine recovered from

amino acid analysis and that of the Nor-Mab-Ser'

should be the same on a molar basis,
20
EXAMPLE 13

(DMP) may be combined with 19.11 g/ul of 70 mM
L-phenylalanine amide in 5 mM EDTA (pH 6.5). The
TRANSESTERIFICATION USINGA
reaction may be initiated by the addition of 15ul of 22
TETRAPEPTIDE MODEL
mg/ml carboxypeptidase Yenzyme (CPD-Y). At preset
This
example
illustrates the synthesis of Benzoyl-Thr
time intervals, the reaction may be sampled by remov
ing 10 ul aliquots and diluting with 200 ul of acetoni 25 Val-Ser-(14 C)OMe from Benzoyl-Thr-Val-Ser-Ser.
trile. Aliquots may be taken at the following approxi About 5 to 10 mM of Benzoyl-Thr-Val-Ser-Ser
mate times: time 0 (prior to adding the enzyme), 1 min (BTVSS) may be dissolved in 2 ml of 50 mM sodium
ute, 5 minutes, 10 minutes, 20 minutes, 40 minutes, 1 phosphate/phosphoric acid buffer (pH 3.5) containing 1
mM EDTA and 0.25 M 14C-methanol (MeOH). The
hour, 2 hours, and 3 hours.
The samples may then be subjected to high pressure 30 reaction may be initiated by the addition of 5 M of
liquid chromatography (HPLC) using a reverse phase carboxypeptidase Y enzyme. At preset time intervals,
C-18 column developed with a linear gradient con the reaction may be sampled by removing 0.2 ml ali
structed from two solvents. A first solvent (A) can be quots and diluting with 0.2 ml of acetonitrile, then add
90% of 50 mM triethylamine phosphate (TEAP) (pH3) 35 ing 0.1 ml of 0.12 Macetic acid.
The samples may then be subjected to high pressure
with 10% acetonitrile, and the second solvent (B) can liquid
chromatography (HPLC) using a reverse phase
be 80% acetonitrile with 20% solvent A. TEAP may be C-18
column developed with a linear gradient con
prepared by titrating 50 mM phosphoric acid with dis
tilled triethylamine to pH 3. A gradient can be devel structed from two solvents. A first solvent (A) can be
of 10 mM sodium acetate, 5% acetonitrile pH 4.5
oped over a 5 minute time period and can be initiated by 95%
and the second (B) can be 60% acetonitrile. A gradient
mixing solvents A and B at the proportions of 1 part A can
be developed over a 30 min time period and can be
and 0 part B and ended with 40 parts A and 60 parts B.
by mixing solvents A and B at the proportions
The flow rate can be maintained at 1.5 ml per min. The initiated
of
1
part
A and 0 parts B and ended with 40 parts A and
BGAPA should disappear with the concommittant
B.
The flow rate can be maintained at 1.0ml per
appearance of BGAPP-amide product and free alanine. 45 60 parts
.
The peptide should elute and be free of phenylalanine
The peptide should elute and be free of methanol and
amide, BGAPA, and Ala.
BTVS
(hydrolyzed BTVSS). Separate amino acid anal
Separate amino acid analyses of the HPLC fraction ysis should
the peptide to contain one residue
should show the peptide to contain one residue each of each of Thr,show
Val
and
a Ser methyl ester. The specific
Benzoyl, Gly, Ala, Pro, and Phe. The specific activity SO activity of both the serine
methyl ester recovered from
of both the phenylalanine amide recovered from amino amino
acid
analysis
and
that
of the peptide should be the
acid analysis and the phenylalanine amide in the peptide same on a molar basis.
should be the same on a molar basis.
EXAMPLE 12

EXAMPLE 14
55

TRANSPEPTIDATION WITH
ANTI-ASPARAGINE
SYNTHETASE MONOCLONAL ANTIBODY

ANTI-ASPARAGINE
SYNTHETASE MONOCLONAL ANTIBODY

This example illustrates the synthesis of C-Nor-C(14C)Ser anti-asparagine synthetase monoclonal anti
body (Nor-Mab-Ser') from anti-asparagine synthetase
monoclonal antibody (Mab). About 0.2 mM of Mab
may be dissolved in 2 ml of 50 mM sodium carbonate
buffer (pH 9.5) containing 1 mM EDTA and 0.25 M
14-C-serine. The reaction may be initiated by the addi
tion of 5 M of carboxypeptidase Y enzyme. At preset
time intervals, the reaction may be sampled by remov

TRANSESTEREFICATION USING
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This example illustrates the synthesis of 14C methyl
C-nor-Anti-asparagine synthetase monoclonal antibody
ester ("methyl-Nor-Mab) from anti-asparagine synthe
tase monoclonal antibody (Mab). About 0.2 mM of Mab
may be dissolved in 2 ml of 50 mM sodium phosphate/phosphoric acid buffer (pH 3.5) containing 1 mM
EDTA and 0.25 M 14-C-Methanol. The reaction may
be initiated by the addition of 5M of carboxypeptidase

Y enzyme. At preset time intervals, the reaction may be
sampled by removing 0.2 ml aliquots and diluting with

5,234,820
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0.2 ml of acetonitrile, then adding 0.1 ml of 0.12 M
acetic acid.
The samples may then be subjected to high pressure

liquid chromatography (HPLC) using a reverse phase
C-18 column developed column developed with a linear
gradient constructed from two solvents. A first solvent
(A) can be 95% of 10 mM sodium acetate, 5% acetoni
trile pH 4.5 and the second (B) can be 60% acetonitrile.
A gradient can be developed over a 30 min time period
and can be initiated by mixing solvents A and B at the
proportions of 1 part A and 0 parts B and ended with 40
parts A and 60 parts B. The flow rate can be maintained
at 1.0 ml per min. The 'methyl-Nor-Mab should elute
and be free of methyl and Nor-Mab (hydrolyzed Mab).
Separate amino acid analysis should show the "methyl
Nor-Mab to contain one residue of methyl serine ester.
The specific activity of both the methyl serine ester
recovered from amino acid analysis and that of the
methyl-Nor-Mab should be the same on a molar basis.
We claim:

34

acid by catalysis at acidic or basic pH with an exo
peptidase enzyme to form the bound protein, the
coupling reaction being between the amine or alco
hol group of the nucleophile within the internedi
ate and the C-terminus carboxylic acid group of the
protein or the carbonyl group of the amino acid
residue penultimate to the C-terminus of the pro

10

15

tein; and
wherein the bound protein is a straight chain of the
protein, nucleophile and auxiliary substance
bonded together or a straight chain of the protein,
nucleophile, linker and auxiliary substance, and
only two sites on each of the nucleophile and linker
as well as only one site on each of the protein and
auxiliary substance are chain binding sites.
3. A method for preparing a labeled protein, compris
ling:
coupling a nucleophile and a protein having a C-ter
minus amino acid with the C-terminus as a carbox

20

ylic acid group, and an 1) amino acid penultimate
to the C-terminus amino acid having a carboxy
group in a medium at acidic or basic pH and in the
presence of an exopeptidase enzyme to form an
adduct, said nucleophile being an amino acid,
amino acid derivative, amine or 1) alcohol having
an amine group or an alcohol group and a side
chain with a distinctive reactive substituent se
lected from the group consisting of sulfhydryl,
hydroxyl, activated hydroxyl, olefinyl, activated
ester, amino, azidyl, hydrazinyl, phosphoramidoyl,
boronyl, ferrocenyl, ferro complexes and mixtures
thereof, wherein the concentration of said enzyme
is from about 1 pM to 1 mM, and the coupling is

1. A method for forming a protein bound to an auxil
iary substance, comprising:
coupling a nucleophile to a protein having a C-ter
minus amino acid with the C-terminus as a carbox
ylic acid group, and an amino acid having a car 25
bonyl group penultimate to the C-terminus amino
acid by catalysis at acidic or basic pH with an exo
peptidase enzyme to form an adduct, wherein the
nucleophile is an amino acid derivative having an
amine group and a side chain with a distinctive 30
reactive substituent, and the coupling is between
the amine group of the nucleophile and the C-ter
minus carboxylic acid group of the protein or the
carbonyl group of the amino acid penultimate to
between the amine or alcohol group of the nucleo
35
the C-terminus of the protein; and,
phile within the adduct and the C-terminus carbox
binding the adduct to the auxiliary substance or its
ylic acid group of the protein or the carbonyl
combination with a linker arm to form the bound
group of the amino acid penultimate to the C-ter
protein, wherein the auxiliary substance or combi
minus of the protein;
nation has a specifically reactive group that is cor
combining a label and a linker arm to form a combina
relatively reactive toward the distinctive reactive
tion, said label being fluoroescent, nuclear mag
substituent of the adduct, and the specifically reac
netic, phosphorescent, colorimetric, magnetic,
tive group and the distinctive reactive substituent
electron resonant or spectrometric and having at
react with each other without substantially involv
least one reactive group, said linker arm being a
ing other groups of the protein to accomplish the
flexible
or semi-flexible chain having a specifically
binding; and
45
reactive group that is correlatively reactive with
wherein the bound protein is a straight chain of the
the distinctive reactive substituent and another
protein, nucleophile and auxiliary substance
functional group that is reactive toward the reac
bonded together or a straight chain of the protein,
tive group of the label, and the combining being
nucleophile, linker and auxiliary substance bonded
between the reactive group of the label and the
together, and only two sites on each of the nucleo SO
functional group of the linker arm; and
phile and linker as well as only one site on each of
binding the adduct and the combination to form the
the protein and auxiliary substance are chain bind
labeled protein, the binding being between the
ing sites.
distinctive reactive substituent and the specifically
2. A method for forming a protein bound to an auxil
reactive group; wherein,
55
iary substance, comprising:
the correlative reactivity of the specifically reactive
binding a nucleophile to the auxiliary substance or its
group and the distinctive reactive substituent result
combination with a linker arm to form an interme
in their reaction with each other without substan
diate, wherein the nucleophile is an amino acid
tially involving other groups of the protein; and
derivative having an amine group or an alcohol
wherein the labeled protein is a straight chain of the
group and with a reactive substituent and the auxil 60
protein, nucleophile, linker and label bonded to
iary substance or combination has a reactive group
gether, and only two sites on each of the nucleo
that is reactive toward the reactive substituent of
phile and linker as well as only one site on each of
the nucleophile, and the binding is between the
the protein and label are chain binding sites.
reactive substituent and the reactive group; and
4. A method for preparing a labeled protein, compris

coupling the intermediate to a protein having a C-ter 65 1ng:
minus amino acid with the C-terminus as a carbon
combining a label and a linker arm to form a combina
ylic acid group, and an amino acid having a car
tion, said label being fluorescent, nuclear magnetic,
boxyl group penultimate to the C-terminus amino
phosphorescent, colorimetric or spectrometric and

35
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having at least one combining group, and said
linker arm being a flexible or semi-flexible chain
having a specifically reactive group that is or is
rendered non-reactive with the combining group of

36

wherein the labeled protein is a straight chain of the
protein, nucleophile, linker and label bonded to

the label and another functional group that is reac- 5
tive toward the combining group of the label, and
the combining is between the combining group of
the label and the functional group of the linker arm;
binding the combination and a nucleophile to form an
intermediate, said nucleophile being an amino acid, O
amino acid derivative, amine or alcohol having an
amine group or an alcohol group and a side chain
with a distinctive reactive substituent that is reac
tive toward the specifically reactive group of the
combination, and the binding being between the 15
distinctive reactive substituent and the specifically
reactive group; and
coupling the intermediate and a protein having a
C-terminus amino acid having a carbonyl group
with the C-terminus as a carboxylic acid group, 20
and an amino acid penultimate to the C-terminus
amino acid in a medium at acidic or basic pH and in
the presence of an exopeptidase enzyme to form
the labeled protein, wherein the concentration of
the enzyme is from about 1 pm to 1 mM, and the 25
coupling is between the amino or alcohol group of
the nucleophile within the intermediate and the
C-terminus carboxylic acid group of the protein or
the carbonyl group of the amino acid penultimate
30
to the C-terminus of the protein; and

35
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gether, and only two sites on each of the nucleo
phile and linker as well as only one site on each of

the protein and label are chain binding sites.
5. A method according to claim 3 or 4 wherein the
coupling conditions are basic and the nucleophile is an

amino acid, amino acid derivative or amine, and the
reaction is conducted for at least about 5 seconds.

6. A method according to claim 3 or 4 wherein the
protein, nucleophile and enzyme are combined in an
aqueous mixture, wherein the aqueous mixture is
formed by:
(a) combining the protein and the nucleophile to form
a mixture;
(b) adjusting the pH of the mixture to within a range
of about 2.0 to 10.5; and
(c) adding the enzyme to the mixture.
7. A method according to claim 3 or 4 wherein the

reaction between the distinctive reactive substituent

and the specifically reactive group is a non-competitive
reaction which does not involve other functional
groups of the protein or a competitive reaction which is
controlled to provide substantially selective reaction
between the specifically reactive group and distinctive
reactive substituent relative to the reaction of either of
the specifically reactive group and the distinctive reac
tive substituent with other functional groups of the
protein.
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